Medtronic (NYSE:MDT) announced a definitive agreement on Tuesday to acquire Scientia Vascular, a privately held medical technology firm specializing in high-performance access products for neurovascular procedures.
The deal is valued at $550 million, with additional provisions for customary adjustments and potential earn-out payments based on future performance milestones.
The acquisition centers on Scientia’s proprietary microfabrication technology, which produces exceptionally flexible and navigable guidewires and microcatheters.
These tools, including the Aristotle® and Zoom Wire collections, are designed to help surgeons navigate the tortuous anatomy of the brain more quickly.
In stroke care, where "time is brain," the ability to reach an occlusion or aneurysm with higher precision can significantly improve patient outcomes and reduce long-term disability.
The transaction includes the transition of approximately 310 Scientia employees, currently based in Salt Lake City, Utah, into Medtronic’s Neurovascular business within its Neuroscience Portfolio.
Medtronic expects the deal to close in the first half of its fiscal year 2027, subject to regulatory approvals.